Farxiga (Dapagliflozin Propanediol) Patent Expiration, LOE Window & CMS Spending

Farxiga (Dapagliflozin Propanediol) by AstraZeneca: FDA Orange Book core substance LOE 2030-06-16 (last listed 2041-10-01), 15 AB generics, $6.11B 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAstraZeneca
FDA Application & PathwayN202293 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2030-06-16
Last Listed Patent or Exclusivity Date2041-10-01
Orange Book Patents (*PED Extensions)33 patents (17 *PED)
Active AB-Rated Generic Competitors15
2024 CMS Total Public Spend$6.11B
2024 Medicare Part D Spend$5.29B
2024 Medicaid Spend$816.9M
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AstraZeneca across sibling Meru public-data platforms.